Not finding it? Sign in to also search OpenAlex live.
-
Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey2025 Patient Preference and Adherence article Medicine Platelet Disorders and Treatments Open access
Jaap Jan Zwaginga, Srikanth Nagalla, Mark van der Linden, Caroline Kruse, Mervyn Morgan, Cecilie Yssing, +2 more
1citations -
Congenital amegakaryocytic thrombocytopenia presenting with a new thrombopoietin receptor (MPL) pathogenic variant: An instructive neonatal case2022 Journal of Paediatrics and Child Health article Medicine Platelet Disorders and Treatments Open access
Inez M Vanholder, Ginette M. Ecury‐Goossen, Jop Admiraal, Leendert Porcelijn, Rosalina ML van Spaendonk, Samantha Claudia Gouw
1citations -
CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes2021 Stem Cell Reports article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kathrin Olschok, Lijuan Han, Marcelo A. S. Toledo, Janik Böhnke, Martin Graßhoff, Ivan G. Costa, +14 more
25citations -
CALR frameshift mutations in MPN patient-derived iPS cells accelerate maturation of megakaryocytes2021 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kathrin Olschok, Lijuan Han, Marcelo A. S. Toledo, Janik Böhnke, Martin Graßhoff, Ivan G. Costa, +14 more
0citations -
Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry2024 Cell Communication and Signaling article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Bhuria, Tobias J. Franz, Conny K. Baldauf, Martin Böttcher, Nicolas Chatain, Steffen Koschmieder, +5 more
18citations -
Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies
Andrew Charles Perkins, Vincent Ribrag, William E. Shomali, Rosa María Ayala, Claire N. Harrison, Stephen T. Oh, +2 more
14citations -
Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Vikas Gupta, John O Mascarenhas, Haris Ali, David M. Ross, Abdulraheem Yacoub, Tania Jain, +27 more
10citations -
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia2022 New England Journal of Medicine article Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Régis Peffault de Latour, Austin Gladston Kulasekararaj, Simona Iacobelli, Sofie Rosanne Terwel, Riley Cook, Morag Griffin, +44 more
324citations -
Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Blood disorders and treatments Open access
Britta Hoechsmann, Philippe Schafhausen, Fabian Beier, Michael Heuser, Joerg Westermann, Beatrice Drexler, +10 more
0citations